[go: up one dir, main page]

MX2017004816A - Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa. - Google Patents

Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa.

Info

Publication number
MX2017004816A
MX2017004816A MX2017004816A MX2017004816A MX2017004816A MX 2017004816 A MX2017004816 A MX 2017004816A MX 2017004816 A MX2017004816 A MX 2017004816A MX 2017004816 A MX2017004816 A MX 2017004816A MX 2017004816 A MX2017004816 A MX 2017004816A
Authority
MX
Mexico
Prior art keywords
methods
ulcerative colitis
predicting clinical
clinical outcomes
subjects afflicted
Prior art date
Application number
MX2017004816A
Other languages
English (en)
Inventor
Singh Sharat
Jain Anjali
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017004816A publication Critical patent/MX2017004816A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona métodos para predecir el resultado clínico de una muestra de un sujeto que tiene colitis ulcerosa (CU), que comprende determinar un perfil de marcadores de pronóstico y clasificar al sujeto como un respondedor o un no respondedor. Los métodos pueden usarse para monitorear y predecir la progresión de la UC, determinando la probabilidad de que la CU progrese rápida o lentamente en un individuo con base en la presencia o nivel de al menos un marcador en una muestra. Los métodos también se pueden usarse para predecir la regresión de CU, determinando la probabilidad de que la CU retroceda rápida o lentamente en un individuo.
MX2017004816A 2014-10-20 2015-10-20 Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa. MX2017004816A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066209P 2014-10-20 2014-10-20
US201462086512P 2014-12-02 2014-12-02
US201562160551P 2015-05-12 2015-05-12
PCT/IB2015/058087 WO2016063223A1 (en) 2014-10-20 2015-10-20 Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis

Publications (1)

Publication Number Publication Date
MX2017004816A true MX2017004816A (es) 2017-08-02

Family

ID=54540132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004816A MX2017004816A (es) 2014-10-20 2015-10-20 Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa.

Country Status (5)

Country Link
US (1) US20170219605A1 (es)
EP (1) EP3210027B1 (es)
CA (1) CA2965095A1 (es)
MX (1) MX2017004816A (es)
WO (1) WO2016063223A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
US20220102008A1 (en) * 2020-09-30 2022-03-31 Genentech, Inc. Methods and systems for placebo response modeling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
US8838481B2 (en) 2011-07-26 2014-09-16 Golba Llc Method and system for location based hands-free payment
CN104634955B (zh) 2009-10-26 2016-09-14 雀巢产品技术援助有限公司 检测抗-tnf药物和自身抗体的试验
US20130040835A1 (en) * 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
AU2012346861A1 (en) * 2011-11-30 2014-06-19 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
SG11201502646RA (en) * 2012-10-05 2015-05-28 Nestec Sa Methods for predicting and monitoring mucosal healing

Also Published As

Publication number Publication date
EP3210027B1 (en) 2019-04-17
CA2965095A1 (en) 2016-04-28
EP3210027A1 (en) 2017-08-30
WO2016063223A1 (en) 2016-04-28
US20170219605A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
Henriksen et al. The future of blood-based biomarkers for Alzheimer's disease
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
MX373248B (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX384485B (es) Deteccion temprana de preeclampsia.
MX2017004816A (es) Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa.
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
WO2014160237A3 (en) Methods of prognosing preeclampsia
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
BR112016021309B8 (pt) Método para detecção de alfa-amilase em açúcares ou intermediários
UA95657U (uk) Спосіб прогнозування зрощення перелому
NZ743812A (en) Prognostic method and kits useful in said method
UA95605U (uk) Спосіб прогнозування зрощення перелому
UA95656U (uk) Спосіб прогнозування зрощення перелому
UA95628U (uk) Спосіб прогнозування зрощення перелому
UA95580U (uk) Спосіб прогнозування зрощення перелому
UA95623U (uk) Спосіб прогнозування зрощення перелому
UA95606U (uk) Спосіб прогнозування зрощення перелому